Pas­cal So­ri­ot: As­traZeneca 'on track' to hit big $40B goal, cap­ping years-long turn­around cam­paign

For the past year or so, Covid-19 has dom­i­nat­ed the nar­ra­tive around As­traZeneca. And for good rea­son: The phar­ma gi­ant has shipped 2.6 bil­lion dos­es of its Ox­ford-part­nered vac­cine world­wide, and it’s been rack­ing up new or­ders of Evusheld, a long-act­ing an­ti­body de­signed to pro­tect the 2% of the glob­al pop­u­la­tion who are im­muno­com­pro­mised.

But fo­cus­ing on that on­ly would miss an­oth­er key suc­cess sto­ry here, ac­cord­ing to CEO Pas­cal So­ri­ot.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER